Clinical Trial Update: Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy [Phase 2]

View source ↗

Summary

Phase 2 safety and effectiveness study of RWJ-445380, a Cathepsin-S inhibitor, in patients with active rheumatoid arthritis despite methotrexate, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RWJ-445380 Cathepsin-S inhibitor (RWJ-445380)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED